8-K: Forward Industries Recasts Financials Amid Losses, Going Concern Doubt
Sentiment:
Financial Statement Recast
Forward Industries, Inc. has reclassified its OEM and retail segments as discontinued operations and reported significant losses, raising substantial doubt about its ability to continue as a going concern.
Capital raiseThe company plans to attempt to obtain debt or equity financing to fund its ongoing operations.In July and September 2024, the company converted $2,200,000 of payables due to Forward China into 2,200 shares of Series A-1 convertible preferred stock to maintain Nasdaq listing standards.On February 11, 2025, the company entered into a third agreement with Forward China to convert an additional $225,000 of payables into 225 shares of Series A-1 convertible preferred stock to meet the Stockholders Equity Rule.
Worse than expectedLoss from continuing operations increased dramatically by 3393.5% in Fiscal 2024 and 146.0% in Q1 Fiscal 2025.Net revenues from continuing operations declined by 11.9% in Fiscal 2024 and 10.1% in Q1 Fiscal 2025.Gross profit and gross margin from continuing operations also saw significant declines.The company recorded substantial goodwill impairment charges in both Fiscal 2024 and Q1 Fiscal 2025, indicating reduced asset values and future performance expectations.The explicit statement of 'substantial doubt about our ability to continue as a going concern' signals severe financial distress.The loss of the largest design customer's insulin patch program is expected to cause a material decrease in future revenues.
Summary
- Forward Industries, Inc. has reclassified its Original Equipment Manufacturer (OEM) and retail distribution segments as discontinued operations for all periods presented, reflecting a strategic shift.
- The OEM segment was committed for sale in March 2025 and sold in May 2025 to Forward China, a related party, to satisfy outstanding payables.
- The retail distribution segment ceased operations in July 2023 due to recurring losses and was fully discontinued by September 30, 2024.
- The company reported a loss from continuing operations of $2,166,000 for Fiscal 2024, a significant increase from $62,000 in Fiscal 2023.
- For the three months ended December 31, 2024, the loss from continuing operations was $897,775, compared to $365,355 for the same period in 2023.
- Net revenues from continuing operations decreased by 11.9% to $19,991,000 in Fiscal 2024 from $22,686,000 in Fiscal 2023.
- Net revenues from continuing operations for the three months ended December 31, 2024, decreased by 10.1% to $4,624,449 from $5,141,832 in the prior year period.
- Goodwill impairment charges totaled $200,000 in Fiscal 2024 (Kablooe reporting unit) and an additional $225,000 for the three months ended December 31, 2024 (IPS reporting unit).
- The company's largest design customer notified it in December 2024 of plans to discontinue an insulin patch program, which is expected to cause a material decrease in revenues starting in the second quarter of Fiscal 2025.
- Management believes there is substantial doubt about the company's ability to continue as a going concern for the next 12 months due to recurring losses, accumulated deficit, and the anticipated revenue decrease.
Sentiment
Score: 2
Explanation: The filing indicates severe financial distress, with significant and increasing losses, substantial doubt about the company's ability to continue as a going concern, and the loss of a major customer. While some discontinued operations showed income, the core continuing operations are struggling, and the company relies heavily on related-party financing to maintain Nasdaq compliance.
Positives
- Income from discontinued operations, net of tax, was $215,592 for Fiscal 2024, a positive shift from a loss of $3,674,528 in Fiscal 2023.
- Income from discontinued operations, net of tax, was $189,710 for the three months ended December 31, 2024, compared to $11,135 in the prior year period.
- The company regained compliance with Nasdaq's Minimum Bid Price Rule and Stockholders Equity Rule in July 2024, following a reverse stock split and preferred stock conversions.
Negatives
- Loss from continuing operations increased significantly to $2,166,179 in Fiscal 2024 from $62,129 in Fiscal 2023.
- Loss from continuing operations for the three months ended December 31, 2024, was $897,775, compared to $365,355 for the same period in 2023.
- Net revenues from continuing operations decreased by 11.9% in Fiscal 2024 and 10.1% in the first quarter of Fiscal 2025.
- Gross profit from continuing operations decreased by 27.4% in Fiscal 2024 and 21.4% in the first quarter of Fiscal 2025, with gross margin declining.
- Operating loss from continuing operations increased by 3424.6% in Fiscal 2024 and 146.0% in the first quarter of Fiscal 2025.
- Goodwill impairment charges of $200,000 (Fiscal 2024) and $225,000 (Q1 Fiscal 2025) reflect reduced expected future performance of reporting units.
- The company had an accumulated deficit of $19,637,140 at September 30, 2024, and $20,345,205 at December 31, 2024.
- Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months.
- The largest design customer is discontinuing a key program, expected to cause a material decrease in revenues starting in the second quarter of Fiscal 2025.
- Stockholders' equity was below $2,500,000 at December 31, 2024, necessitating further preferred stock conversion to maintain Nasdaq compliance.
Risks
- Substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient liquidity.
- Significant customer concentration, with two customers representing 48.4% of net revenues in Fiscal 2024 and 43.1% in Q1 Fiscal 2025.
- Material decrease in revenues expected from Q2 Fiscal 2025 due to the loss of the largest design customer's insulin patch program.
- Inability to raise additional capital or obtain additional borrowings on acceptable terms, or at all, to fund operations or strategic opportunities.
- Reliance on Forward China, a related party, for sourcing and as a significant creditor, which could impact operational flexibility and financial stability.
- Risk of failing to satisfy Nasdaq's Stockholders Equity Rule during the monitoring period until July 24, 2025, which would require an immediate hearing to maintain listing.
- Variability of revenues and results of operations due to highly variable orders and short lead times from large customers.
- Estimates and assumptions used in financial reporting, particularly for goodwill impairment and inventory valuation, could differ significantly from actual results.
Future Outlook
Management expects a material decrease in revenues beginning in the second quarter of Fiscal 2025 due to the loss of its largest design customer's insulin patch program. The company plans to initiate cost reduction measures, including a reduction in force, and will seek flexibility on payment terms from Forward China. It also intends to attempt to obtain debt or equity financing to fund ongoing operations, though there is no assurance such financing can be obtained.
Management Comments
- Management plans to initiate cost reduction measures in Fiscal 2025 to mitigate the impact of the loss of our largest customer, including a reduction in force which was communicated in December 2024.
- Management also plans to seek flexibility on payment terms for ongoing purchases from Forward China and attempt to obtain debt or equity financing to fund its ongoing operations.
Industry Context
Forward Industries is transitioning its business model, exiting the OEM and retail distribution segments to focus solely on its design services for medical and technology customers. This strategic shift aims to streamline operations but comes at a time of significant financial distress, marked by declining revenues in its core design segment and the loss of a major customer. The company's high customer concentration in the design segment exposes it to substantial risk from individual customer decisions, as evidenced by the discontinuation of the insulin patch program. The reliance on related-party financing and transactions with Forward China highlights potential governance and operational dependencies that are not uncommon in smaller, distressed public companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Nasdaq Compliance | Regained compliance with Nasdaq's Minimum Bid Price Rule and Stockholders Equity Rule in July 2024 after a 1-for-10 reverse stock split and preferred stock conversions. | 2024-07-01 | Temporarily resolved delisting threats, but ongoing monitoring and further capital raise (preferred stock conversion) were required due to continued equity decline. |
| Reverse Stock Split | A 1-for-10 reverse stock split of common stock was authorized by shareholders and approved by the Board of Directors. | 2024-06-18 | Aimed to increase share price to meet Nasdaq's Minimum Bid Price Rule, retroactively adjusted all share and per-share amounts. |
| Preferred Stock Issuance | Issued 2,200 shares of Series A-1 Convertible Preferred Stock to Forward China in July and September 2024 by converting $2,200,000 of accounts payable. | 2024-07-01 | Increased shareholders' equity to meet Nasdaq's Stockholders Equity Rule, but introduced a new class of preferred stock with senior liquidation preference and conversion rights to a related party. |
| Preferred Stock Issuance (Subsequent) | Agreed to issue an additional 225 shares of Series A-1 Convertible Preferred Stock to Forward China by converting $225,000 of payables. | 2025-02-11 | Further increased shareholders' equity to maintain compliance with the Stockholders Equity Rule, indicating ongoing financial fragility and reliance on related-party support. |
Related Party Transactions
- Forward China, owned by the company's former CEO and Chairman Terence Wise, acts as the company's exclusive buying agent and supplier in the Asia-Pacific region.
- Service fees paid to Forward China were $891,000 in Fiscal 2024 and $1,266,000 in Fiscal 2023 (included in discontinued operations).
- Purchases from Forward China were $7,862,000 in Fiscal 2024 and $12,799,000 in Fiscal 2023.
- In November 2023, Forward China agreed to limit collection of outstanding payables (as of October 30, 2023) to $500,000 in any 12-month period; remaining balance covered by this agreement was approximately $4,881,000 at December 31, 2024.
- The company converted $2,200,000 of payables due to Forward China into 2,200 shares of Series A-1 convertible preferred stock in July and September 2024.
- On February 11, 2025, an additional $225,000 of payables to Forward China was agreed to be converted into preferred stock.
- A $600,000 unsecured promissory note payable to Forward China (originally $1,600,000) bears 8% interest and has an extended maturity date of June 30, 2025.
- The OEM business was sold to Forward China in May 2025, with payments including $200,000 at closing and three $150,000 installments due on July 31, 2025, August 31, 2025, and September 30, 2025.
- Revenues from the sale of Koble products (brand owned by Terence Wise's Justwise Group Ltd.) were $380,000 in Fiscal 2024 and $2,058,000 in Fiscal 2023 (included in discontinued operations).
- Costs incurred under an agreement with Justwise were $20,000 in Fiscal 2024 and $127,000 in Fiscal 2023 (included in discontinued operations).
- Revenue from a customer whose principal owner is an immediate family member of Jenny P. Yu (Managing Director of Forward China and significant shareholder) was $523,000 in Fiscal 2024 and $626,000 in Fiscal 2023 (included in discontinued operations).
Stakeholder Impact
- Shareholders face significant risk of further share price depreciation, potential dilution from future capital raises, and the ultimate risk of delisting due to ongoing financial instability and going concern doubt.
- Employees are impacted by cost reduction efforts, including a reduction in force communicated in December 2024, due to the loss of a major customer and overall financial struggles.
- Forward China, as a major related-party creditor and supplier, is significantly impacted by the company's financial health, having converted substantial payables into preferred stock and extended debt maturity dates to support the company.
- Customers, particularly the largest design customer, are impacted by the discontinuation of programs, while new customers are being sought to offset revenue declines.
Next Steps
- Initiate cost reduction measures in Fiscal 2025, including a reduction in force, to mitigate the impact of lost revenue.
- Seek flexibility on payment terms for ongoing purchases from Forward China.
- Attempt to obtain debt or equity financing to fund ongoing operations.
- Continue to be subject to a Nasdaq Panel Monitor until July 24, 2025, regarding compliance with the Stockholders Equity Rule.
- Make remaining payments of $150,000 each on July 31, 2025, August 31, 2025, and September 30, 2025, to Forward China related to the OEM business sale.
- Repay the $600,000 promissory note to Forward China on or prior to its extended maturity date of June 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 2010-02-01 | Forward Switzerland and its European logistics provider entered into a Representation Agreement. |
| 2010-02-01 | Forward Switzerland entered into a guarantee agreement with a Swiss bank. |
| 2011-02-28 | Initial term of the bank letter of guarantee expired, with automatic one-year renewals thereafter. |
| 2018-01-18 | Company issued a $1,600,000 unsecured promissory note payable to Forward China. |
| 2020-10-01 | Company began selling smart-enabled furniture under the Koble brand. |
| 2021-02-01 | Shareholders approved the 2021 Equity Incentive Plan. |
| 2021-03-01 | The 2011 Long Term Incentive Plan expired. |
| 2022-12-16 | Effective date for ASU 2019-11 (Credit Losses) for fiscal years beginning after. |
| 2023-04-01 | Fixed portion of sourcing fee to Forward China reduced from $100,000 to $83,333 per month. |
| 2023-07-01 | Nasdaq notified the company of non-compliance with the Minimum Bid Price Rule. |
| 2023-07-01 | Company decided to cease operations of its retail distribution segment (Retail Exit). |
| 2023-08-31 | Agreement with Justwise Group (Koble brand owner) was effective until this date, then extended month-to-month. |
| 2023-09-30 | Retail segment inventory classified as discontinued assets held for sale. |
| 2023-10-01 | New sourcing agreement with Forward China became effective, further reducing the fixed portion of the sourcing fee to $65,833 per month. |
| 2023-10-30 | Forward China agreed to limit collection of outstanding payables to $500,000 in any 12-month period. |
| 2023-11-01 | FASB issued ASU 2023-07, Segment Reporting, effective for fiscal years beginning after December 15, 2023. |
| 2023-11-30 | Justwise Group agreement extended month-to-month until this date. |
| 2023-12-01 | FASB issued ASU 2023-09, Income Taxes Improvements to Income Tax Disclosures, effective for fiscal years beginning after December 15, 2024. |
| 2024-02-01 | Nasdaq notified the company of non-compliance with the Stockholders Equity Rule. |
| 2024-04-01 | Company presented a plan of action to the Nasdaq Hearings Panel. |
| 2024-06-18 | A 1-for-10 reverse stock split of common stock became effective. |
| 2024-07-01 | Company regained compliance with Nasdaq's Minimum Requirements. |
| 2024-07-01 | First Accounts Payable Conversion Agreement with Forward China became effective. |
| 2024-09-01 | Second Accounts Payable Conversion Agreement with Forward China became effective. |
| 2024-09-16 | Date of report (earliest event reported) and consent of independent registered public accounting firm. |
| 2024-09-30 | Retail segment was fully discontinued. |
| 2024-09-30 | Annual goodwill impairment test performed, resulting in a $200,000 charge for Kablooe. |
| 2024-10-01 | Options granted to non-employee directors to purchase 48,020 shares of common stock. |
| 2024-10-01 | Promissory note maturity date extended to June 30, 2025. |
| 2024-10-31 | New sourcing agreement with Forward China expired. |
| 2024-11-01 | Company and Forward China agreed to extend sourcing agreement until April 30, 2025, reduce fixed fee, and change payment terms. |
| 2024-11-01 | FASB issued ASU 2024-03, Income Statement Reporting Comprehensive Income—Expense Disaggregation Disclosures. |
| 2024-11-30 | Cash balance (excluding discontinued OEM segment) was approximately $2,000,000. |
| 2024-12-01 | Largest design customer notified the company of its plan to discontinue the insulin patch program. |
| 2024-12-01 | Reduction in force communicated to mitigate revenue reduction. |
| 2024-12-27 | Original filing date of the Annual Report on Form 10-K for the fiscal year ended September 30, 2024. |
| 2024-12-31 | Goodwill impairment test for IPS reporting unit performed, resulting in a $225,000 charge. |
| 2025-01-01 | FASB issued ASU 2025-01, Clarifying the Effective Date of ASU 2024-03. |
| 2025-01-31 | Cash balance (excluding discontinued OEM segment) was approximately $2,600,000. |
| 2025-02-01 | Payments under renewed New York lease commence. |
| 2025-02-11 | Company entered into a third agreement with Forward China to convert $225,000 of payables into preferred stock. |
| 2025-02-13 | Original filing date of the Quarterly Report on Form 10-Q for the period ended December 31, 2024. |
| 2025-03-01 | Company committed to a plan to sell the OEM segment of its business. |
| 2025-05-09 | Buying Agency and Supply Agreement with Forward China expired. |
| 2025-05-16 | Company completed the sale of its OEM business to Forward China. |
| 2025-07-24 | End of Nasdaq Panel Monitor period. |
| 2025-07-31 | Payment of $150,000 due to Forward China for OEM sale. |
| 2025-08-31 | Payment of $150,000 due to Forward China for OEM sale. |
| 2025-09-30 | Final payment of $150,000 due to Forward China for OEM sale. |
| 2025-12-31 | Promissory note to Forward China matures. |
| 2026-12-16 | Effective date for ASU 2024-03 (Income Statement Expense Disaggregation) for fiscal years beginning after. |
| 2027-12-31 | Effective date for ASU 2024-03 (Income Statement Expense Disaggregation) for interim periods within fiscal years beginning after. |
Recommendation
strong sellThe company faces severe financial distress, evidenced by substantial and increasing losses from continuing operations, a significant accumulated deficit, and an explicit 'going concern' warning from management and auditors. The loss of its largest design customer, which accounted for over 30% of consolidated net revenues in Fiscal 2024, is expected to materially decrease future revenues. Despite efforts to regain Nasdaq compliance through a reverse stock split and related-party preferred stock conversions, the company's stockholders' equity remains precarious, necessitating further such actions. The reliance on related-party financing and the ongoing operational challenges, including goodwill impairments, indicate a highly speculative investment with a high risk of further value erosion or delisting.
Keywords
Forward Industries, FORD, SEC filing, 8-K, financial statements, discontinued operations, OEM segment, retail distribution, design services, going concern, goodwill impairment, Nasdaq compliance, related party transactions, revenue decline, net loss, liquidity, cost reduction, customer concentration
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.